We are studying a combination of tislelizumab and chemotherapy for patients with stage III PD-L1 positive lung cancer. The aim is to see if this treatment improves surgery success and survival rates.
Health conditions and diseases that the clinical trial is designed to study and treat.
Stage III Non-Small Cell Lung Cancer (NSCLC) is an advanced form of lung cancer where the disease has spread to nearby lymph nodes and possibly other structures in the chest. It is characterized by the presence of PD-L1, a protein that can affect how the immune system responds to cancer.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.